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ABSTRACT
Objective: The objective of this EBM review is to determine whether or not “Is oral aloe vera
effective in reducing symptoms in adults with Irritable Bowel Syndrome (IBS) symptoms?”
Study Design: Systematic review of three English, randomized, controlled, double-blind studies,
including one cross-over study, were selected based on their relevance to the clinical question.
The studies were published in 2006, 2011, and 2015.
Data Sources: Three RCTs analyzing the effects on IBS symptoms of drinking aloe vera daily
compared to a placebo drink were found using PubMed.
Outcomes Measured: Various patient-reported IBS symptom questionnaires were utilized to
compare the effectiveness of drinking oral aloe vera versus the placebo on reducing symptoms in
adults with irritable bowel syndrome (IBS). K. Davis used the Global Summated Symptom
Score.2 Storsrud S. used the IBS Symptom Severity Scoring System (IBS-SSS).4 H.A. Hutchings
used the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL).3
Results: In the Davis et al study, there was no significant improvement of IBS symptoms
between the aloe vera and placebo group (p= 0.12). The NNT was -11.2 In the Storsrud et al pilot
study, there was no significant improvement in IBS symptoms in using the Aloe barbadensis
Mill. extract in comparison to the placebo (p=0.09). The NNT was 5.4 In the Hutchings et al
study, there was no significant improvement of IBS symptoms between the aloe vera and
placebo group (p>0.05). The mean change from baseline was 69-74 points on the ISBQOL score
for period 1.3
Conclusions: Although two of the studies showed trends towards improvement, all three studies
were not considered statistically significant in showing improvement in symptoms in IBS
symptoms. Therefore, oral aloe vera is not considered effective in reducing symptoms in adults
with irritable bowel syndrome. Additionally, after my further research via WebMD on the safety
of drinking aloe vera, I found varying results for whom it was considered safe. I would suggest
that future studies first assess its safety before evaluating it effectiveness in reducing IBS
symptoms.
Key words: Aloe vera and IBS
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Introduction
Irritable bowel syndrome (IBS) largely affects the United States in population and cost. IBS
is characterized by a collection of symptoms such as cramping, abdominal pain, bloating,
diarrhea, and constipation for at least three months.5 The condition does not permanently harm
the large intestine, nor lead to serious disease like cancer. However, the frustrating symptoms
may hinder the patient’s quality of life, such as in traveling and working. Because no definitive
cure exists, patients and providers are often searching for additional natural remedies for patients
to try at home. This systemic review evaluates three double-blind, randomized, controlled trials,
including a cross-over study, assessing the effectiveness of drinking aloe vera on symptomtic
improvement in adults with IBS.
Up to 20 percent of U.S. adults suffer with IBS symptoms, making it one of the most
common disorders diagnosed by doctors.5 Women, individuals younger than 50 (usually
beginning before age 35) and people with a family member who has IBS are most likely to
develop IBS.5 The total direct cost related to IBS was $1.35 billion dollars and $619 per patient.4
IBS accounts for 3.5 million physician visits per year, accounting for 25% of all GI visits.
Furthermore, only 10-25% of symptomatic patients seek medical care.4
The cause of IBS is not well understood and there is no cure. Although numerous treatments
for IBS exist, each patient responds differently, and many still suffer with the frustrating IBS
symptoms. Some physicians recommend diet alterations such as 4-5 smaller meals/day, high
fiber meals, and 6-8 glasses of water/ day.5 Physicians may also recommend medications such as
fiber supplements, anti-diarrheal medications such as loperimide, antispasmodic agents such as
dicyclomine or peppermint oil, antidepressants such as TCAs or SSRIs, or IBS medications such
as Lubiprostone.5 Cognitive and stress relief therapy are also often supplemental suggestions.
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These include CBT, psychotherapy, and hypnotherapy.5 Although several treatment options exist
for patients with IBS, many patients are still searching for an effective option that is natural and
easily maintainable.

Objective
The objective of this selective EBM review is to determine whether or not “Is oral aloe vera
effective in reducing symptoms in adults with irritable bowel syndrome (IBS)?”

Methods
The criteria used for the selection of studies included the population, intervention,
comparison, outcomes, and study type. The population consisted of individuals >18 y.o. with
IBS according to Rome II or III criteria. The interventions included drinking aloe vera solutions
of 50 ml QID, 60 ml BID, or 250 mg of AVH200 dissolved in water BID. The comparisons
included drinking the placebo solution of 50 ml QID, 60 ml BID or 50 ml QID, or 60 mg tablets
of ascorbic acid and excipients dissolved in water BID. The outcomes were evaluated via
patient-reported questionnaires assessing the improvement of IBS symptoms with the use of
daily aloe vera. The studies chosen were 3 randomized, double-blind, placebo controlled clinical
trials, one of which being a cross-over study. The studies were published in 2006, 2011, and
2015.2,3,4 See Table 1 for demographics of each study.
The data were collected by searching the key words aloe vera and IBS on English, peerreviewed journals via PubMed. Articles were selected based on their relevance to the clinical
question and that the study outcomes were patient oriented (POEMS). Inclusion criteria included
studies that were randomized, double-blind, and controlled including adults >18 y.o. who were
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diagnosed with IBS. Exclusion criteria excluded studies performed before 2001 or previous
Cochrane systemic reviews on my topic. The statistics reported were numbers needed to treat
(NNT), relative benefit increase (RBI), absolute benefit increase (ABI), mean change from
baseline, and p-values.
Table 1: Demographics and Characteristics of Included Studies
Study
Davis2

Type

#
Age
Patients (years)
Double- 54
18-65
blind
RTC

Hutchings3 Double- 110
blind
RTC
(Cross
over)

>18

Storsrud4

18-65

Double- 68
blind
RTC

Inclusion
Criteria
Adults 18-65y.o.
who satisfy the
Rome II criteria
who had
previously tried
and failed
conventional
management
Adults >18y.o.
diagnosed with
IBS according to
the Rome II
criteria for > 1
year and had
received previous
treatment; c/o
abdominal pain,
seeking further
treatment; willing
and able to give
consent to be
randomized in
the study;
females with a
negative
pregnancy test

Adults ages 1865y.o. with IBS
according to the
Rome III criteria,
and were

Exclusion
Criteria
On
medications
other than
related to
IBS, other
medical
conditions,
pregnant
Significant
GI tract
disease, had
undergone
previous GI
surgery,
were known
defaulters at
clinic and
might be
difficult to
follow up,
were on
drugs that
might affect
motility, or
had a current
or recent Hx
of drug or
alcohol
abuse
Other GI dz
explaining
the sxs, food
allergy or
intolerance

W/D

Interventions

1mo
-9
3mo
-8

Aloe vera
(50 ml QID
for 3 months)

63

Aloe vera
(60 mg BID
for 5 months,
2 week wash
out period, 5
months alt. tx

5

Aloe
barbadenses
Mill. Extract
(250 mg in
water BID,
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evaluated by a
other than
gastroenterologist lactose
intolerance,
other severe
disease, sxs
indicating
other severe
dz

before
breakfast and
late in the
evening for 4
weeks

Outcomes measured
Various patient-reported IBS symptom questionnaires were utilized to compare the
effectiveness of drinking oral aloe vera daily versus the placebo on reducing symptoms in adults
with irritable bowel syndrome (IBS). K. Davis used the Global Summated Symptom Score for
abdominal pain, distension, satisfaction with bowel habit, and global impact of symptoms on
well-being. A reduction of ≥ 50 points qualified as improvement. S. Storsrud used the IBS
Symptom Severity Scoring System (IBS-SSS), which assesses pain severity, pain frequency,
bloating severity, bowel habit dissatisfaction, and life interference. An improvement was defined
as a reduction of ≥ 50 points on the IBS-SSS questionnaire. H.A. Hutchings used continuous
data from the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL) involving 8
subscales: emotional health, mental health, sleep, energy, physical functioning, diet, social role,
and physical role.

Results
Three double-blind, placebo controlled RTCs were used to determine whether drinking
aloe vera improves symptoms in adults with IBS. In the Davis et al study, there was no
significant improvement of IBS symptoms between the aloe vera and placebo group (p= 0.12).
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For this study, 54 subjects were either randomized to receive 50 ml QID of an aloe vera solution
or the 50 ml of placebo solution for 3 months. Patients were selected from gastroenterology
clinics from two large hospitals in London and were allocated their medication through the
central pharmacy of each hospital. Both the experimental and placebo solutions were pink syrup
flavored with mango. Inclusion criteria included patients who had IBS according to the Rome II
criteria, aged 18-65, and had previously tried but failed conventional management with
antispasmodics, bulking agents, and dietary intervention. Exclusion criteria for this study
excluded patients who were on medications other than those related to IBS, had other medical
conditions, including those related to the bowel, or were pregnant or at risk of pregnancy.2
All of the patients, researchers, and doctors remained blind throughout the study. The
data were presented at dichotomous data, and at the end of three months, the response by
intention to treat was 5 of 18 (28%) and 5 of 26 (18%) in the placebo and active group
respectively. At the conclusion of the study, 13 out of 54 subjects (24%) were lost to follow-up.
Six patients withdrew due to nausea and vomiting. The outcome was measured by change in
global summated symptom score and global impact of symptoms on well-being; a reduction of ≥
50 points qualified as improvement. The experimental group was then compared to the placebo
group results. The NNT was -11. Therefore, for every 11 patients treated with oral aloe vera, one
less would show improvement in comparison to the placebo treatment.2 The RBI was -0.32 and
the ABI was -0.09. The results for calculations of efficacy may be found in Table 2.
In the Storsrud et al pilot study, there was no significant improvement in IBS symptoms
in using the Aloe barbadensis Mill. extract in comparison to the placebo (p=0.09). For this study,
patients were selected from referrals to gastroenterology outpatient clinic as well as from
advertisements in local newspapers. Inclusion criteria included adult patients (18-65y.o.) who
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had signed a written informed consent, had IBS according to the Rome III criteria, were
evaluated by a gastroenterologist, and have the ability to understand and willingness to comply
to the study procedures. Exclusion criteria excluded those with other gastrointestinal disease(s)
explaining the symptoms, food allergy or intolerance other than lactose intolerance, other severe
disease(s) such as malignancy, severe heart disease, kidney disease neurological disease,
symptoms indicating other severe disease(s) such as weight loss, gastrointestinal bleeding or
fever, or severe psychiatric disease. Patients who were already using of aloe vera products or
were pregnant or lactating were also excluded. Sixty-eight patients were eligible and 33 were
randomized to receive Aloe barbadenses Mill. extract in water (250 mg AVH200®, 60 mg
ascorbic acid and excipients) and 35 to the matching placebo BID, before breakfast and late in
the evening, for 4 weeks. Patients completed weekly questionnaires to assess IBS symptom
severity.4
Researchers, doctors, and patients were kept blind throughout the study, and the data
were presented as dichotomous data. At the end of 4 weeks, the response by intention-to-treat
was assessed with drop-outs counted as non-responders and missing data imputed from the
previous assessment using the last observation carried forward technique, and was all included in
the analysis. At the conclusion of the study, 55% of the aloe vera group and 31% of the placebo
group qualified as an improvement in symptoms, and 5 subjects were lost to follow-up.
Improvement was defined by a reduction of ≥50 points on the IBS-SSS questionnaire after 4
weeks. A follow-up symptom questionnaire via a telephone was additionally administered 2
weeks after the conclusion of the treatment period. The results of the experimental group were
compared to the placebo group. NNT was calculated as 5, meaning for every 5 subjects treated
with aloe vera, one patient would statistically improve as compared to the placebo treatment. The
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RBI was 0.77 and the ABI was 0.24.4 Results for calculations of efficacy may be found in Table
2.
Table 2
Davis et al2
Storsrud et al4

RBI
-0.32
0.77

ABI
-0.09
0.24

NNT
-11
5

p-value
0.12
0.09

In the Hutchings et al study, there was no significant improvement of IBS symptoms
between the aloe vera and placebo group (p>0.05). This study was a multi-centre prospective
randomized, double-blind, cross-over study of 110 subjects. Inclusion criteria included those
who were at least 18 years, diagnosed as suffering with IBS according to the ROME II Criteria
for at least one year and had received precious treatment, complaining of abdominal pain and
were seeking further treatment. The subjects must have been able and willing to give consent to
be randomized into the study. Females patients were included if they were taking adequate
contraceptive precautions and had a negative pregnancy test at baseline, patients on medication
for stable medical conditions not considered to yield an effect on the study were eligible for
recruitment, and specific medications for diarrhea or constipation were permitted. Exclusion
criteria excluded those who had other significant GI tract disease, had undergone previous GI
tract surgery, were known to be defaulters at clinic and might be difficult to follow up, were on
drugs which might affect motility, or had a current of recent history of drug or alcohol abuse.
Qualifying subjects in 3 hospitals in South West Whales, UK were randomized into groups of 55
patients to drink a 60 ml of aloe vera drink twice a day (Group AB) or a matching placebo drink
twice a day (Group BA). Group AB drank the aloe vera for 5 months, had a 2-week “wash out”
period, and continued with another 5 months with the placebo, while group BA began with the
placebo and and ended with the aloe vera for period 1.3
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The researchers, doctors, and patients were kept blind throughout the study, and the data
were continuous and not convertible to dichotomous data. The subjects were analyzed based on
“intention to treat,” and improvement was assessed using The Irritable Bowel Syndrome Quality
of Life Questionnaire (IBSQOL) at baseline, at the end of study period 1 (5 months), and at the
end of study 2 (10 months).3 The mean change from baseline was 69-74 points on the ISBQOL
score for period 1. Independent sample T-tests or chi-square were also used to assess baseline
differences in the groups before the study. By the end of the 10 months, only 47 out of the 110
(43%) finished the entire study, and 63 subjects (57%) were lost to follow-up.3 Results for
calculations of efficacy may be found in Table 3.
Table 3

Hutchings et al3

Mean change from baseline at p-value
the end of period 1 using the
IBSQOL
69-74
> 0.05

Discussion
In the Davis et al study, there was no evidence that drinking aloe vera daily benefits
patients with IBS (p= 0.12). Nausea and vomiting with drinking the solution may have affected
the outcome. However, the majority of the nausea and vomiting came from the placebo group
and therefore, was not considered to be a significant side effect. According to the Davis et al
study, the results were unable to rule out the possibility that improvement occurred in patients
with diarrhea or alternating IBS while taking aloe vera (AV). Therefore, authors of the study
suggested that further investigations be warranted in patients with diarrhea predominant IBS.2
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In the Storsrud et al study, several limitations may have affected this study. First of all,
this was a pilot study which was aimed to find tendencies towards group differences to detect
potentially clinically meaningful differences, and to plan future studies based on the findings.4
Now, a larger study is claimed to be proceeding with a sample size based on the observed effect
size in this study.4 Additionally, although the groups were randomized, the aloe vera group had a
tendency towards higher severity of IBS symptoms at baseline, and some of the results could
possibly be due to regression towards the mean. However, when using the adequate relief
endpoint, a trend defined as improvement IBS-SSS reduction was noted. The ongoing larger
study should help these limitations be overcome.4
In the Hutchings et al study, although both study groups were entirely compliant with the
allocated treatments and all treatment containers were returned empty, poor recruitment
numbers, a large number of patients withdrawing from the study, and the long treatment period
all may have had an effect on the results. Moreover, only about 10% of over 1000 patients
initially identified with symptoms suggestive of IBS were recruited, which could indicate that the
sample was not truly representative of the wide spectrum of IBS patients. Additionally, the
requirement to discontinue certain medications prior to entering the study may have further
impacted those recruited.3
The combination of decreased recruitment rate and the number of drop-outs throughout
the study reduced the power of the study. Patients discontinued the study for a variety of reasons
including an increase in symptoms, which was noted more markedly in the Aloe vera group.3
Aloe is a cactus-like plant found in the United States growing in hot, dry environments
and comes in two forms, gel and latex. Although not proven to be effective in many cases, aloe
vera may be taken by mouth or applied topically to the skin for a vast variety of conditions.
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According to WebMD, topical application of aloe vera may possibly be an effective treatment
for acne, burns, genital herpes, pruritic rashes, oral submucous fibrosis, and psoriasis.1 Ingestion
of aloe vera may possibly be effective for weight loss and constipation.1 It is important to note,
however, that the U.S Food and Drug administration does not precisely regulate herbs and
supplements, so there is no guarantee of the strength, purity, and safety of aloe vera. According
to an overview in WedMD, applying aloe vera gel topically is “likely safe.”1 However, ingesting
aloe vera is “possibly safe” when taken short term.1 Furthermore, ingesting aloe latex long-term
is “possible unsafe” at any dose, but “likely unsafe” in high doses.1 Side effects may cause
stomach pain and cramps, and long-term use of large amounts of aloe latex could cause diarrhea,
kidney problems, blood in the urine, low potassium, muscle weakness, weight loss, and heart
disturbances.1 Taking aloe latex 1 gram daily for several days can be fatal.1 People who are
pregnant, or have diabetes, intestinal conditions such as Crohn's disease, ulcerative colitis, or
obstruction, hemorrhoids, kidney issues, or recent surgery should avoid use of aloe vera. Also,
aloe vera has a major negative drug interaction with digoxin and should be avoided.1

Conclusion
All three studies were not considered statistically significant in showing symptomatic
improvement in adults with IBS. The Storsrud et al study was the only study to show a trend
towards improvement of IBS symptoms. Therefore, oral aloe vera is not considered effective in
reducing symptoms in adults with irritable bowel syndrome.
Additionally, after my further research via WebMD on the safety of drinking aloe vera, I
found varying results for whom it was considered safe. I would suggest that future studies first
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assess the safety of ingesting the aloe vera. Then, once statistically determined, supplemental
studies could assess its effectiveness in reducing IBS symptoms.
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